drugset / Trial / NCT02727608

Complement Inhibitor Eculizumab in Clinical Islet Transplantation

NCT02727608

Phase 2 Completed 3 enrolled Uppsala University
NaSingle-groupOpen-labelPrevention

Summary

This is a dual centre, single arm, exploratory study of the possibility to use eculizumab (Soliris) to prevent/reduce destruction of islets of Langerhans after portal infusion of the islets in patients with diabetics accepted for islet transplant.

Timeline

Start
2016-05-15
Primary completion
2018-05
Completion
2018-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Eculizumab Monoclonal antibody 900 mg Intravenous

Indications